10,260 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the fourth quarter, Holdings Channel reports. The fund acquired 10,260 shares of the specialty pharmaceutical company’s stock, valued at approximately $126,000.

Several other hedge funds also recently added to or reduced their stakes in KALV. Quantbot Technologies LP bought a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $31,000. China Universal Asset Management Co. Ltd. bought a new position in KalVista Pharmaceuticals during the 4th quarter worth approximately $49,000. New York State Common Retirement Fund grew its position in shares of KalVista Pharmaceuticals by 1,860.4% in the 3rd quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 9,451 shares in the last quarter. Strs Ohio bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $104,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at approximately $109,000.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par bought 4,474 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were purchased at an average cost of $14.74 per share, with a total value of $65,946.76. Following the completion of the acquisition, the insider now directly owns 4,743,157 shares in the company, valued at $69,914,134.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 4,474 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was acquired at an average cost of $14.74 per share, with a total value of $65,946.76. Following the completion of the purchase, the insider now directly owns 4,743,157 shares in the company, valued at $69,914,134.18. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Benjamin L. Palleiko sold 22,802 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $14.11, for a total transaction of $321,736.22. Following the sale, the chief financial officer now owns 187,315 shares of the company’s stock, valued at $2,643,014.65. The disclosure for this sale can be found here. Insiders sold a total of 75,978 shares of company stock worth $1,070,918 over the last 90 days. 12.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KALV. HC Wainwright raised their price target on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Needham & Company LLC restated a “buy” rating and set a $35.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, April 11th.

KalVista Pharmaceuticals Trading Up 2.8 %

Shares of NASDAQ:KALV opened at $10.78 on Monday. The firm’s 50 day moving average is $12.28 and its two-hundred day moving average is $11.34. The firm has a market capitalization of $454.81 million, a P/E ratio of -3.42 and a beta of 0.88. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.21 and a 52 week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.09). Analysts predict that KalVista Pharmaceuticals, Inc. will post -3.05 EPS for the current year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.